• Resonance Health is developing a non-invasive MRI liver fibrosis device
• The device aims to compete with biopsy for liver fibrosis assessment
• The company is set to launch the device into a growing market driven by MASH therapeutics
• Resonance Health is hosting a webinar on June 9th to discuss the device progress
• The company expects to achieve profitability in FY26

Resonance Health Limited has announced the progress of its MRI Liver Fibrosis Device, a non-invasive solution aiming to compete with biopsy for liver fibrosis assessment. The device utilizes multi-parametric MRI analysis on standard MRI hardware, offering a 15-minute scan without the need for contrast agents or extra equipment. The company is leveraging its proven Software-as-a-Medical-Device (SaMD) platform, which is already serving over 400 MRI clinical sites in 48 countries. The announcement highlights the significant unmet need for accurate non-invasive liver fibrosis assessment, with over 1.5 billion people living with chronic liver disease. The device is set to launch into a growing market driven by the approval of MASH therapeutics and the explosion of GLP-1 trials, which require non-invasive endpoints. Resonance Health is hosting a webinar on June 9th to discuss the device progress and FY26 portfolio update.

FY26 Revenue guidance: $16.0M, EBITDA guidance: $2.6M, EBITDA margin: 14%

Resonance Health expects to achieve profitability in FY26, with the new Liver Fibrosis device launching into a financially self-sustaining business.